AbCellera Biologics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABCL research report →
About the company
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs.
- CEO
- Carl Hansen
- IPO
- 2020
- Employees
- 596
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $2.48B
- P/E
- -17.07
- P/S
- 31.27
- P/B
- 2.62
- EV/EBITDA
- -16.11
- Div Yield
- 0.00%
- Gross Margin
- 79.07%
- Op Margin
- -267.61%
- Net Margin
- -181.75%
- ROE
- -14.86%
- ROIC
- -13.84%
- Revenue
- $75.13M · 160.56%
- Net Income
- $-146,412,000 · 10.10%
- EPS
- $-0.49 · 10.91%
- Op Income
- $-217,103,000
- FCF YoY
- 6.89%
- 52W High
- $8.42
- 52W Low
- $2.75
- 50D MA
- $5.35
- 200D MA
- $4.38
- Beta
- 1.20
- Avg Volume
- 7.65M
Get TickerSpark's AI analysis on ABCL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | Hayden Michael R | other | 111,701 |
| Jun 11, 26 | Quake Stephen | other | 111,701 |
| Jun 11, 26 | Montalbano John S. | other | 111,701 |
| Jun 1, 26 | Sandor Victor | other | 0 |
| May 14, 26 | Montalbano John S. | buy | 20,000 |
| Feb 27, 26 | Thermopylae Holdings Ltd. | buy | 38,000 |
| Feb 26, 26 | Thermopylae Holdings Ltd. | buy | 177,457 |
| Feb 27, 26 | Booth Andrew | buy | 42,600 |
| Jan 1, 26 | Booth Andrew | other | 808,898 |
| Jan 1, 26 | Hansen Carl L. G. | other | 2,106,505 |
Our ABCL coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ABCL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.